Journals / Journal of Neurological Sciences (Turkish) / 2013 / Cilt: 30 - Sayı: 3

Kronik Kazanılmış Hepatoserebral Dejenerasyon: CaNa2EDTA'nın Etkisi

Chronic Acquired Hepatocerebral Degeneration: The Effect of CaNa2EDTA

Pages
579–582
Publication Date
2022-10-19
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Our case withmanganese-related chronic acquired dramatically hepatocerebral degeneration responded wellto the CaNa2EDTA treatment.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Introduction: Hepatocerebral degeneration caused by chronic liver insufficiency is a rarecondition with the pathophysiology of a possible manganese toxification.
📊
Key Findings & Data:Its clinicalpresentation includes parkinsonism, walking ataxia and psychiatric findings.Case Report: A 78-year-old female patient was admitted with 5-year-long sustainingcomplaints of imbalance with increasing severity, falls and low-speed walking.
💡
Conclusion & Impact:Our case withmanganese-related chronic acquired dramatically hepatocerebral degeneration responded wellto the CaNa2EDTA treatment.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Introduction: Hepatocerebral degeneration caused by chronic liver insufficiency is a rarecondition with the pathophysiology of a possible manganese toxification. Its clinicalpresentation includes parkinsonism, walking ataxia and psychiatric findings.Case Report: A 78-year-old female patient was admitted with 5-year-long sustainingcomplaints of imbalance with increasing severity, falls and low-speed walking. The patienthad suffered from HBV-related chronic liver failure. T1 sequences of cranial MRI inspectionrevealed hyperintensity changes in basal ganglion and mesencephalic substantia nigra regions.The blood manganese level of the patient was measured and was found to be 433 nmol/L(normal range: 73-210 nmol/L). The patient received IV CaNa2EDTA. Upon evalution at thethird month of treatment bradykinesia was apparently gone, the walking ataxia and rigiditywere milder, but the restricted upward sight sustained.Conclusion: Numerous researches on the treatment have been published. Our case withmanganese-related chronic acquired dramatically hepatocerebral degeneration responded wellto the CaNa2EDTA treatment.

Özet

Giriş: Hepatoserebral dejenerasyon, kronik karaciğer yetmezliği sonucunda olan,patofizyolojisinde olasılıkla manganez toksikasyonunun olduğu, nadir bir durumdur. Kliniksunumunda, parkinsonism, yürüyüş ataksisi ve psikiyatrik bulgular bulunur.Olgu Sunumu: Yetmiş sekiz yaşındaki bayan hasta yaklaşık 5 yıldır olan ve giderek artandengesizlik, düşmeler ve yürümede yavaşlık şikayetleri ile başvurdu. Hastada HBV'ye bağlıkronik karaciğer yetmezliği tablosu vardı. Kranyal MRG incelemesinde T1 sekanslarındabazal ganglion bölgesinde hiperintens değişiklikler saptandı. Kan manganez düzeyi 433nmol/L saptandı. Hastaya IV CaNa2EDTA uygulandı. Hasta 3. ayında değerlendirildiğindebradikinezisinin belirgin kaybolduğu, hastanın yürüyüş ataksisinin ve rijiditesinin azaldığıgözlendi.Tartışma: Literatürde tedavi ile ilişkili geniş çalışmalar bulunmamaktadır. Olgumuzliteratürde kronik karaciğer hastalığına bağlı gelişmiş hepatoserebral dejenerasyon hastasındaCaNa2EDTA'nın etkinliğini gösteren ilk olgu olması nedeni ile önemlidir.

🔖

Cite This Article

KIYLIOGLU, N., AKYOL, A., AKYILDIZ, U. O., TATAROGLU, C., PARLAZ, A. U. (2022). Kronik Kazanılmış Hepatoserebral Dejenerasyon: CaNa2EDTA'nın Etkisi. Journal of Neurological Sciences (Turkish), Cilt: 30 - Sayı: 3, 579–582. https://ajindex.com/articles/565121

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (7)

  1. Herrero Hernandez E, Discalzi G, Valentini C, et al. Follow-up of patients aff ected by manganese- induced Parkinsonism af ter treatment with CaNa2EDTA. Neurotoxicology. 2006 May;27(3):333-9
  2. Jog MS, Lang AE. Chronic acquired hepatocerebral degeneration: case reports and new insights. Mov Disord. 1995;10: 714- 722
  3. Klos KJ, Ahlskog JE, Josephs KA, et al. Neurologic spectrum of chronic liver f ailure and basal ganglia T1 hyperintensity on magnetic resonance imaging: probable manganese neurotoxicity. Arch Neurol. 2005 Sep;62(9):1385-90
  4. Olanow CW. Manganese-induced parkinsonism and Parkinson's disease. Ann N Y Acad Sci. 2004 Mar;1012:209-23
  5. Papapetropoulos S, Singer C. Management of the extrapyramidal syndrome in chronic acquired hepatocerebral degeneration (CAHD). Mov Disord. 2005 Aug;20(8):1088-9
  6. Park HK, Kim SM, Choi CG, et al. Eff ect of trientine on manganese intoxication in a patient with acquired hepatocerebral degeneration. Mov Disord. 2008 Apr 15;23(5):768-70
  7. Ueki Y, Isozaki E, Miyazaki Y, et al. Clinical and neuroradiological improvement in chronic acquired hepatocerebral degeneration af ter branched-chain amino acid therapy. Acta Neurol Scand 2002;106: 113-116.